Moleculin wraps treatment in first stage of AML trial with $7.3m cash on hand
The US biotech says all 90 Part A patients in its Annamycin study have finished therapy, with data due early 2027 and a small cash balance.
16 Nov 2026 · Moleculin Biotech, Inc. MBRX · Company news
Moleculin Biotech has finished treating the 90 patients in the first stage of its Phase 2/3 MIRACLE study, moving its lead leukaemia candidate closer to the readout that will shape the rest of the programme. The company disclosed the milestone alongside third-quarter 2026 results on 16 November.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Moleculin Biotech, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Pipeline & R&DAll →
Pipeline & R&D
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
18 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news
Pipeline & R&D
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
18 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news
Pipeline & R&D
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
18 Nov 2026 · Optimi Health Corp. OPTH · Company news
Pipeline & R&D
Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial
18 Nov 2026 · Can-Fite BioPharma Ltd. CANF · Company news
Pipeline & R&D
Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma
17 Nov 2026 · Inhibrx Biosciences, Inc. INBX · Company news
Pipeline & R&D
Adagene and City of Hope launch Phase 1 trial of ivonescimab plus muzastotug in colorectal cancer
17 Nov 2026 · Adagene Inc. ADAG · Company news